Correction to Lancet Neurol 2020; 19: 998-1009

No authors listed

Published Erratum

No authors listed. Lancet Neurol. 2021 Jan.

. 2021 Jan;20(1):e1.

doi: 10.1016/S1474-4422(20)30437-3. Epub 2020 Nov 17.

No abstract available

Erratum for

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I, Hubeaux S, Kappos L, Hauser SL. Wolinsky JS, et al. Lancet Neurol. 2020 Dec;19(12):998-1009. doi: 10.1016/S1474-4422(20)30342-2. Epub 2020 Oct 29. Lancet Neurol. 2020. PMID: 33129442 Clinical Trial.